These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

417 related items for PubMed ID: 12634224

  • 21. Radiographic progression and remission rates in early rheumatoid arthritis - MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial.
    Hetland ML, Stengaard-Pedersen K, Junker P, Østergaard M, Ejbjerg BJ, Jacobsen S, Lottenburger T, Hansen I, Tarp U, Andersen LS, Svendsen A, Pedersen JK, Lauridsen UB, Ellingsen T, Lindegaard H, Pødenphant J, Vestergaard A, Jurik AG, Hørslev-Petersen K, CIMESTRA study group.
    Ann Rheum Dis; 2010 Oct; 69(10):1789-95. PubMed ID: 20444751
    [Abstract] [Full Text] [Related]

  • 22. A randomized, double-blind, and placebo-controlled multicenter clinical trial of a novel cytotoxic T-lymphocyte antigen-4 fusion protein, Leining, in Chinese active rheumatoid arthritis patients with an inadequate response to methotrexate.
    Fan W, Zhao DB, Hu SX, Xu HJ, Zhang X, Zhang MJ, Chen ZW, Zhang FX, Zhu P, Li XF, Bi LQ, Zhou B, Bao CD.
    Rheumatol Int; 2014 Nov; 34(11):1519-27. PubMed ID: 24671501
    [Abstract] [Full Text] [Related]

  • 23. Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens.
    Zintzaras E, Dahabreh IJ, Giannouli S, Voulgarelis M, Moutsopoulos HM.
    Clin Ther; 2008 Nov; 30(11):1939-55. PubMed ID: 19108784
    [Abstract] [Full Text] [Related]

  • 24. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial.
    Smolen JS, Emery P, Fleischmann R, van Vollenhoven RF, Pavelka K, Durez P, Guérette B, Kupper H, Redden L, Arora V, Kavanaugh A.
    Lancet; 2014 Jan 25; 383(9914):321-32. PubMed ID: 24168956
    [Abstract] [Full Text] [Related]

  • 25. Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial.
    Bingham CO, Mendelsohn AM, Kim L, Xu Z, Leu J, Han C, Lo KH, Westhovens R, Weinblatt ME, GO-FURTHER Investigators.
    Arthritis Care Res (Hoboken); 2015 Dec 25; 67(12):1627-36. PubMed ID: 25623393
    [Abstract] [Full Text] [Related]

  • 26. Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial.
    Hara M, Ishiguro N, Katayama K, Kondo M, Sumida T, Mimori T, Soen S, Nagai K, Yamaguchi T, Yamamoto K, Iguratimod-Clinical Study Group.
    Mod Rheumatol; 2014 May 25; 24(3):410-8. PubMed ID: 24252050
    [Abstract] [Full Text] [Related]

  • 27. Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial.
    Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, Blanco R, Kadva A, Dimonaco S.
    Ann Rheum Dis; 2017 Jul 25; 76(7):1279-1284. PubMed ID: 28389552
    [Abstract] [Full Text] [Related]

  • 28. Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study.
    Takeuchi T, Yamanaka H, Ishiguro N, Miyasaka N, Mukai M, Matsubara T, Uchida S, Akama H, Kupper H, Arora V, Tanaka Y.
    Ann Rheum Dis; 2014 Mar 25; 73(3):536-43. PubMed ID: 23316080
    [Abstract] [Full Text] [Related]

  • 29. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.
    Emery P, Bingham CO, Burmester GR, Bykerk VP, Furst DE, Mariette X, van der Heijde D, van Vollenhoven R, Arendt C, Mountian I, Purcaru O, Tatla D, VanLunen B, Weinblatt ME.
    Ann Rheum Dis; 2017 Jan 25; 76(1):96-104. PubMed ID: 27165179
    [Abstract] [Full Text] [Related]

  • 30. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
    Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK.
    Arthritis Rheum; 2004 May 25; 50(5):1400-11. PubMed ID: 15146409
    [Abstract] [Full Text] [Related]

  • 31. Comparison of Tripterygium wilfordii Hook F with methotrexate in the treatment of active rheumatoid arthritis (TRIFRA): a randomised, controlled clinical trial.
    Lv QW, Zhang W, Shi Q, Zheng WJ, Li X, Chen H, Wu QJ, Jiang WL, Li HB, Gong L, Wei W, Liu H, Liu AJ, Jin HT, Wang JX, Liu XM, Li ZB, Liu B, Shen M, Wang Q, Wu XN, Liang D, Yin YF, Fei YY, Su JM, Zhao LD, Jiang Y, Li J, Tang FL, Zhang FC, Lipsky PE, Zhang X.
    Ann Rheum Dis; 2015 Jun 25; 74(6):1078-86. PubMed ID: 24733191
    [Abstract] [Full Text] [Related]

  • 32. Rapid onset of efficacy predicts response to therapy with certolizumab plus methotrexate in patients with active rheumatoid arthritis.
    Kang YM, Park YE, Park W, Choe JY, Cho CS, Shim SC, Bae SC, Suh CH, Cha HS, Koh EM, Song YW, Yoo B, Lee SS, Park MC, Lee SH, Arendt C, Koetse W, Lee SK.
    Korean J Intern Med; 2018 Nov 25; 33(6):1224-1233. PubMed ID: 29294598
    [Abstract] [Full Text] [Related]

  • 33. A multicenter, randomized, double-blind clinical trial of combination therapy with Anbainuo, a novel recombinant human TNFRII:Fc fusion protein, plus methotrexate versus methotrexate alone or Anbainuo alone in Chinese patients with moderate to severe rheumatoid arthritis.
    Chen XX, Dai Q, Huang AB, Wu HX, Zhao DB, Li XF, Hu SX, Yang NP, Tao Y, Xu JH, Jiang LD, Bao CD.
    Clin Rheumatol; 2013 Jan 25; 32(1):99-108. PubMed ID: 23053688
    [Abstract] [Full Text] [Related]

  • 34. Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial.
    O'Dell JR, Curtis JR, Mikuls TR, Cofield SS, Bridges SL, Ranganath VK, Moreland LW, TEAR Trial Investigators.
    Arthritis Rheum; 2013 Aug 25; 65(8):1985-94. PubMed ID: 23686414
    [Abstract] [Full Text] [Related]

  • 35. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study.
    Kremer J, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z, Han J, Taylor P.
    Arthritis Rheum; 2010 Apr 25; 62(4):917-28. PubMed ID: 20131276
    [Abstract] [Full Text] [Related]

  • 36. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial.
    Bakker MF, Jacobs JW, Welsing PM, Verstappen SM, Tekstra J, Ton E, Geurts MA, van der Werf JH, van Albada-Kuipers GA, Jahangier-de Veen ZN, van der Veen MJ, Verhoef CM, Lafeber FP, Bijlsma JW, Utrecht Rheumatoid Arthritis Cohort Study Group.
    Ann Intern Med; 2012 Mar 06; 156(5):329-39. PubMed ID: 22393128
    [Abstract] [Full Text] [Related]

  • 37. Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis.
    Chen DY, Chou SJ, Hsieh TY, Chen YH, Chen HH, Hsieh CW, Lan JL.
    J Formos Med Assoc; 2009 Apr 06; 108(4):310-9. PubMed ID: 19369178
    [Abstract] [Full Text] [Related]

  • 38. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
    Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, Breedveld FC, Furst DE, Lipsky PE, ATTRACT Study Group.
    Arthritis Rheum; 2005 Apr 06; 52(4):1020-30. PubMed ID: 15818697
    [Abstract] [Full Text] [Related]

  • 39. Rescue of combination therapy failures using infliximab, while maintaining the combination or monotherapy with methotrexate: results of an open trial.
    Ferraccioli GF, Assaloni R, Di Poi E, Gremese E, De Marchi G, Fabris M.
    Rheumatology (Oxford); 2002 Oct 06; 41(10):1109-12. PubMed ID: 12364628
    [Abstract] [Full Text] [Related]

  • 40. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial.
    Soubrier M, Puéchal X, Sibilia J, Mariette X, Meyer O, Combe B, Flipo RM, Mulleman D, Berenbaum F, Zarnitsky C, Schaeverbeke T, Fardellone P, Dougados M.
    Rheumatology (Oxford); 2009 Nov 06; 48(11):1429-34. PubMed ID: 19741011
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.